Small Airways and Inflammation
The small airways in the lungs can be sites of chronic inflammation in patients with asthma.1 As a result, the airways can undergo irreversible structural changes.2 Treating inflammation in the small airways may improve lung function,1 contribute to asthma control,1,3 and reduce the severity of asthma attacks in response to triggers.3 If an ICS does not reach or treat both the large and small airways, underlying chronic inflammation may persist.4,5
QVAR® Inhaled Corticosteroid (ICS) Particle Size
QVAR® is a small-particle inhaled corticosteroid (ICS) that can help patients with mild to moderate persistent asthma control their symptoms.6 The mean particle size of QVAR® is 1.1 µm, meaning that QVAR® distributes throughout the large and small airways.1,7-8*
* The relationship of lung deposition and particle size to clinical efficacy is unknown.
QVAR® (beclomethasone dipropionate HFA) Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age or older. QVAR® is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR® may reduce or eliminate the need for systemic corticosteroids.
Important Safety Information
QVAR® is not a bronchodilator and is not indicated for relief of acute bronchospasm.
CAUTION: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information).
A reduction in growth velocity in growing children and teenagers may occur as a result of inadequate control of chronic diseases such as asthma or from use of corticosteroids for treatment
Common side effects associated with the use of QVAR® and placebo in clinical trials include, but are not limited to, headache (12% and 9% respectively) and pharyngitis (8% and 4% respectively).